Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000669105 | SCV000793810 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2017-08-31 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV001727791 | SCV001976404 | pathogenic | Retinitis pigmentosa 39 | 2021-09-21 | criteria provided, single submitter | clinical testing | This variant was identified as compound heterozygous with NM_206933.4:c.2023C>T. |
Labcorp Genetics |
RCV002531217 | SCV003523494 | pathogenic | not provided | 2022-04-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln933*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Usher syndrome (PMID: 10909849). ClinVar contains an entry for this variant (Variation ID: 553620). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV001727791 | SCV004182393 | pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003453279 | SCV004182394 | pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing |